Amarantus Bioscience Holdings Inc (AMBS)

[DCorleone]

NASDAQ IPO: Why Now? • Core fundamentals have never been stronger and improving – In spite of achieving recent important milestones, share price has declined – Stock unable to hold gains due to short - term trading interests – Greater access to long - term institutional investors and research analysts – Therapeutics pipeline ‘institution - ready’ w/ Elto Phase 2b initiation – Pending Cutanogen acquisition will further drive institutional interest* – Begin participating in biotech bull market: IPO for AMBS onto NASDAQ • Potential of Diagnostics spinout onto NASDAQ creates leverage in negotiating with potential partners/acquirers – Relationship established with key players – Preparing to initiate formal parallel process : AMDX IPO vs. Sale • Strategic Financial Advisor for Sale • Underwriter for IPO • Better financing/negotiation options for AMBS and AMDX on NASDAQ vs. OTC 9 * = upon exercise of exclusive option to acquire Cutanogen Corporation from Lonza